Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment
Authors
Keywords
-
Journal
PROSTATE
Volume 81, Issue 15, Pages 1125-1134
Publisher
Wiley
Online
2021-08-26
DOI
10.1002/pros.24213
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review
- (2021) Young Dong Yu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
- (2021) Maria Adamaki et al. Cancers
- The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
- (2021) Anastasia Mpakali et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
- (2021) Eugene Shenderov et al. PROSTATE
- Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
- (2021) Erin G. Shackleton et al. Cancers
- The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
- (2021) Jamal Majidpoor et al. CLINICAL IMMUNOLOGY
- Prostate cancer cell‐intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone
- (2020) Katie L Owen et al. EMBO REPORTS
- Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
- (2020) Mayassa J. Bou-Dargham et al. BMC CANCER
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
- (2020) Karim Fizazi et al. EUROPEAN UROLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Development of immune checkpoint therapy for cancer
- (2019) Jill M. Fritz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
- (2019) Celestia S. Higano et al. CANCER
- Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy
- (2019) Adriana C. Vidal et al. Cancer Epidemiology
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- New Developments in Mechanisms of Prostate Cancer Progression
- (2018) Nicholas Howard et al. SEMINARS IN CANCER BIOLOGY
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- The Diagnosis and Treatment of Prostate Cancer
- (2017) Mark S. Litwin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune system in cancer metastasis: friend or foe?
- (2017) Louise M.E. Janssen et al. Journal for ImmunoTherapy of Cancer
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
- (2016) Marcela V. Maus et al. ONCOLOGIST
- Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+T cells
- (2016) Ravikumar Muthuswamy et al. PROSTATE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Tumors: Wounds That Do Not Heal--Redux
- (2015) H. F. Dvorak Cancer Immunology Research
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
- (2014) A. J. Garcia et al. MOLECULAR AND CELLULAR BIOLOGY
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
- (2013) Matthew D. Vesely et al. Annals of the New York Academy of Sciences
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence
- (2012) P. J. Dluzniewski et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- CD4 helper T cells, CD8 cytotoxic T cells and FOXP3+ regulatory T cells with respect to lethal prostate cancer
- (2012) Sabina Davidsson et al. MODERN PATHOLOGY
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Tumor Evasion from T Cell Surveillance
- (2011) Katrin Töpfer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
- (2009) Jian Zhang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- Association ofIL10and Other immune response- and obesity-related genes with prostate cancer in CLUE II
- (2009) Ming-Hsi Wang et al. PROSTATE
- SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
- (2008) M. Fasso et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes
- (2008) P. A. Savage et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now